• Home
  • Our Technology
  • Research & Development
  • Products & Services
  • About Us
    • CN
    R & D
    Maternal & Child Health
    Optimizing Health and Well-Being for Women and Children

    According to the well-known DOHaD (developmental origins of health and disease) theory, the mother's nutrition and metabolism have a direct impact on the fetus's growth and development.

    Sedentary lifestyle, obesity, smoking, alcohol consumption, chronic diseases (diabetes, hypertension), and amniotic fluid abnormalities are all maternal risk factors that have been linked to an increased risk of adverse pregnancy outcomes, affecting maternal, fetal and perinatal health.

    Epidemiological studies have shown that almost all adult chronic diseases, such as metabolic diseases, CVD and tumors can be traced back to pregnancy.


    Common pregnancy diseases
    Preeclampsia

    Pre-eclampsia (PE) has a global incidence rate of 3-8% and is a leading cause of maternal and neonatal mortality. PE can progress to eclampsia, which can cause complications like hemolysis, elevated liver enzymes, HELLP syndrome, renal failure, and heart failure. PE also causes fetal growth restriction and premature birth. Long-term effects on pregnant women include an increased risk of postpartum cardiovascular disease.

    Although numerous studies are being conducted to determine the causes of PE and to predict the disease before symptoms appear, the exact pathogenesis of PE is unknown. More advanced methods are needed to improve prediction and diagnosis of PE among women at risk.

    Gestational Diabetes Mellitus

    Women who have gestational diabetes mellitus (GDM) are more likely to develop type 2 diabetes (T2D) later in life. Furthermore, their newborns are more likely to develop respiratory distress syndrome, macrosomia, jaundice, obesity, or other metabolic syndrome.

    If detected early, timely lifestyle intervention can reduce these short- and long-term adverse health effects. However, there is still no reliable method to predict GDM during early pregnancy.

    Overnutrition or Malnutrition

    Malnutrition can alter an individual's developmental trajectory from conception to birth and then to 24 months, resulting in delayed and/or impaired immune, cognitive, and physical development.This deficiency can be irreversible and increase the risk of disease later in life.

    As a result, there is an urgent need to understand the complex biomolecular disturbances caused by nutrient deficiency in various critical windows, as well as the risks that lead to developmental disorders.Maternal nutrition has long been regarded as an essential component of a healthy pregnancy.

    Inadequate macronutrient intake is linked to hyperglycemia and hyperlipidemia, while excessive calorie intake is linked to pregnancy complications like GDM, PE, intrauterine growth restriction, and preterm delivery. Micronutrients are essential for the regulation of maternal and fetal metabolism, oxidative stress, and the structural development of the placenta and other vital fetal organs and tissues.


    Advances in Pregnancy Related Metabolomics Research

    Common pregnancy complications, such as pre-eclampsia (PE) and gestational diabetes mellitus (GDM), may have a lifelong impact on the health of mothers and children. Although a number of studies have been investigated in the past, the mechanisms underlying the disease are still unclear, metabolomics has become one of the hot research tools.

    Pre-eclampsia

    Because preeclampsia (PE) is a multifactorial disease, high-throughput technologies capable of simultaneously identifying multiple markers, rather than traditional tools that only detect a single marker, can be an effective screening method for multifactorial diseases.

    Previous metabolomics studies have shown that some metabolomic markers, such as lipids and amino acids and their derivatives, have good prospects for the early diagnosis of PE. Inflammation, oxidative stress, coagulation, and angiogenesis are all metabolic pathways involving small molecules.

    Gestational Diabetes Mellitus

    Although previous metabolic studies on gestational diabetes mellitus (GDM) have inconsistent results, these studies have identified biomarkers involving specific metabolic groups and metabolic pathways, including amino acid metabolism, steroid hormone biosynthesis, glycerol and phospholipid metabolism, and fatty acid metabolism. However, the sample sizes of most of these studies are small. Metabolomics is a new approach to the systematic study of metabolites and its latest technology offers the opportunity for early diagnosis of GDM and the classification of the risk for secondary chronic diseases in these pregnant women and their offspring.

    Micronutrients

    Micronutrient "features" or "fingerprints" detected by metabolomics techniques as predictive biomarkers of pregnancy complications can provide important information on the relationship between specific micronutrients and pregnancy complications. Many of the key proteins in the body require specific micronutrients to function, so metabolomic screening to identify these micronutrients that may significantly affect related proteins or pathophysiology, will open up new ideas for nutritional intervention and treatment and bring great benefits to mothers and infants.

    Nutrition and Metabolomics in Newborns
    Perinatal and Newborn Care

    Breast milk is necessary for the baby's healthy development. Indeed, during the first weeks of life, breast milk has the ability to modify the newborn's metabolism as well as change its composition in response to the newborn's needs.

    Understanding the composition and role of breast milk is a hot topic in modern research, which made it possible for personalized care based on the need of each newborn. In this regard, metabolomics is an excellent tool for improving commercial formula to better mimic breast milk.

    Furthermore, metabolomics holds promise for detecting drugs and contaminants in breast milk, which will aid in determining its safety under specific conditions or the maternal exposure to environmental toxins.


    R & D Pipeline

    We profile and analyze the dynamic metabolome, which is important for promoting maternal and infant health from pre-conception management to postpartum perinatal care.

    1. Establishing Maternal, Fetal, and Newborn Metabolic Profiles

    Through studies of mother-infant cohort, we compile metabolic information related to adverse outcomes in pregnant women and newborns, to picture the dynamic trajectory throughout their whole life cycle.

    2. Integration of Big Data

    we integrate metabolomics with health big data generated during the whole course, including lifestyle, health status, and medical history to construct the complex disease phenotype of mothers and infants.

    3. Modeling pregnancy and neonatal diseases

    We establish models for risk assessment, disease diagnosis and health monitoring of pregnancy complications and newborn diseases, develop personalized screening methods and treatment plans to fulfill the needs of clinical or health management in different situations.

    Having a Healthy Pregnancy and Prevent Birth Defects
    Non-invasive prenatal testing (NIPT) in high demand

    For pregnant women who are unable or unwilling to undergo invasive prenatal diagnosis, the development and application of new technologies has provided more accurate indicators and screening tools for the risk assessment of fetal anomalies. According to industry estimates, the market for prenatal diagnosis is worth more than 50 billion RMB.

    Newborns per year
    22 Million
    A single test costs
    2,500 to 3,500 RMB
    Chinese Market
    50 Billion
    Project Cooperation
    Perfect Details Define Professionalism

    We have an advanced metabolomics R&D platform and an interdisciplinary professional team. We look forward to partnerships with biopharma, hospitals, universities, research institutes, and government enterprises in the precision medicine industry.

    1. Project Establishment

    Our experienced professionals will provide consulting and help with project setup.

    2. Project Design

    Discuss with our scientific experts about your research interests, to ensure the clinical and analytical needs are met, while achieving the expected project objectives.

    3. Agreement

    A strategic cooperation relationship will be set up between both parties ensuring resource sharing and synergistic development. A written agreement will be signed on the benefits, IP rights, decision-making mechanism, and maintenance costs.

    4. Sample Collection

    We will provide SOPs for sample collection, storage and transportation to help our partners to obtain qualified samples. The full process QC is ensured by our experienced operating team and synchronized information-based sample management system.

    5. Sample Transportation

    Samples are required to be transferred on dry ice while the temperatures are tracked throughout the transportation.

    6. Sample Testing

    We will design appropriate analytical methods according to the project objectives. With the Metabonum, our professional quality management system, high quality and  reproducible metabolomics data is guaranteed.

    7. Data Analysis

    Even facing large sample sizes, our experts still can provide the most accurate annotation and the most comprehensive analytics with the proprietary database UlibMS and processing tool Spectronaut.

    8. Commercialize Research Findings

    Research findings or technology created during the project can be further developed into marketable products for the benefit of the public.

    Parternships and Collaborations

    Are you looking to establish strategic collaboration or partnership opportunity in cancer research with an innovative and progressive research company?  We are interested in collaborations with leading researchers, institutions, and facilities with proven track records. Contact us or leave your message below.

    Metanotitia Inc.

  • Service hotline

    0451-51021416

  • E-mail

    Info@metanotitia.com

  • Address

    HQ: Floor 3-4, Building C4, Building 6, Science and Technology Headquarters, Shenzhen (Harbin) Industrial Park, Zhigu Street, Songbei District, Harbin
    BO: Room 1307,13F Beike Building, Nanshan District,Shenzhen
    • Contact Us
    • Please confirm the information given above is correct, so that we can reach out to you. Metanotitia is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested.
    Send a message
    TOP